Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. (APVO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
apvo · stock forecast · 3 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $4.89
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $4.94 | ↑ 1.00% |
1-day model range: $4.85–$5.03. Peak: $5.03 (+1.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · APVO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-05-12 | Piper Sandler | Maintains | Overweight→Overweight |
| 2021-05-27 | Roth Capital | Maintains | Buy→Buy |
| 2020-11-25 | PiperJaffray | Maintains | Overweight→Overweight |
| 2020-11-25 | Roth Capital | Maintains | Buy→Buy |
| 2020-11-10 | Piper Sandler | Maintains | Overweight→Overweight |
| 2018-04-11 | Roth Capital | Maintains | Buy→Buy |
| 2016-09-09 | PiperJaffray | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Aptevo Therapeutics Inc. (APVO) stock. Of the recent 7 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover APVO.
Analyst Recommendation Trends
APVO analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$8M
↓ 57.4% YoY
Revenue Next Year
$7M
↓ 10.8% YoY
EPS This Year
$-24.13
EPS Next Year
$-21.46
↓ 11.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast APVO EPS of $-24.13 for the current fiscal year, based on estimates from 1 analysts. The APVO revenue forecast is $8M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The APVO stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus APVO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The APVO short-term stock prediction for tomorrow is $4.94 (+1.00%).
Aptevo Therapeutics Inc. trades on NASDAQ under the ticker APVO. The APVO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
APVO forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month APVO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $4.89.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.